Clinical Trial Update: Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Nolatrexed Dihydrochloride with Doxorubicin for recurrent or unresectable liver cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• Nolatrexed Dihydrochloride (nolatrexed dihydrochloride)

Snippet

Sponsor: Eximias Pharmaceutical | Conditions: Liver Cancer | Phase 3 | Status: COMPLETED